CN101300253B - 作为电压门控离子通道调控剂的二环衍生物 - Google Patents

作为电压门控离子通道调控剂的二环衍生物 Download PDF

Info

Publication number
CN101300253B
CN101300253B CN2006800406004A CN200680040600A CN101300253B CN 101300253 B CN101300253 B CN 101300253B CN 2006800406004 A CN2006800406004 A CN 2006800406004A CN 200680040600 A CN200680040600 A CN 200680040600A CN 101300253 B CN101300253 B CN 101300253B
Authority
CN
China
Prior art keywords
pain
group
ring
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800406004A
Other languages
English (en)
Chinese (zh)
Other versions
CN101300253A (zh
Inventor
T·纽伯特
N·奇默曼
A·卡瓦特卡
E·马丁波罗
A·特明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101300253A publication Critical patent/CN101300253A/zh
Application granted granted Critical
Publication of CN101300253B publication Critical patent/CN101300253B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800406004A 2005-09-09 2006-09-08 作为电压门控离子通道调控剂的二环衍生物 Expired - Fee Related CN101300253B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71598005P 2005-09-09 2005-09-09
US60/715,980 2005-09-09
PCT/US2006/034857 WO2007030618A2 (en) 2005-09-09 2006-09-08 Bicyclic derivatives as modulators of voltage gated ion channels

Publications (2)

Publication Number Publication Date
CN101300253A CN101300253A (zh) 2008-11-05
CN101300253B true CN101300253B (zh) 2012-08-22

Family

ID=37686027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800406004A Expired - Fee Related CN101300253B (zh) 2005-09-09 2006-09-08 作为电压门控离子通道调控剂的二环衍生物

Country Status (14)

Country Link
US (4) US7855220B2 (enExample)
EP (1) EP1928871A2 (enExample)
JP (1) JP2009507851A (enExample)
KR (1) KR20080044910A (enExample)
CN (1) CN101300253B (enExample)
AU (1) AU2006287480B2 (enExample)
CA (1) CA2622076A1 (enExample)
IL (1) IL190017A0 (enExample)
MX (1) MX2008003337A (enExample)
NO (1) NO20081725L (enExample)
NZ (1) NZ567132A (enExample)
RU (1) RU2008113836A (enExample)
WO (1) WO2007030618A2 (enExample)
ZA (1) ZA200802977B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
ZA200709961B (en) 2005-05-10 2009-07-29 Vertex Pharma Bicyclic derivatives as modulators of ion channels
EP1888558B1 (en) * 2005-05-16 2011-10-05 Vertex Pharmaceuticals, Inc. Bicyclic derivatives as modulators of ion channels
NZ567132A (en) * 2005-09-09 2011-12-22 Vertex Pharma Bicyclic derivatives as modulators of voltage gated ion channels
AU2006306367A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
EP2308872A1 (en) * 2005-12-21 2011-04-13 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
EP2158183A2 (en) 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
RU2010123876A (ru) * 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
CA2705336A1 (en) 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
CN101978787A (zh) * 2008-04-30 2011-02-16 夏普株式会社 照明装置和显示装置
CN102099356A (zh) * 2008-07-01 2011-06-15 沃泰克斯药物股份有限公司 用作离子通道调节剂的杂环衍生物
PT2300459E (pt) * 2008-07-02 2013-07-04 Hoffmann La Roche Novas fenilpirazinonas utilizadas como inibidores de cinase
EP2323482A4 (en) * 2008-08-06 2011-08-17 Merck & Co Inc SUBSTITUTED DIHYDROISOCHINOLINONE AND ISOCHINOLINDION DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
ES2857687T3 (es) 2013-01-31 2021-09-29 Vertex Pharma Piridona amidas como moduladores de los canales de sodio
US12234221B2 (en) 2018-07-09 2025-02-25 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NAV1.8
SG11202100137TA (en) 2018-07-09 2021-02-25 Lieber Institute Inc PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
CN114901642B (zh) * 2019-12-30 2024-02-23 武汉朗来科技发展有限公司 一种稠环化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
JP2003055209A (ja) * 2001-07-31 2003-02-26 Bayer Ag フェニルナフチル尿素誘導体
EP1506166B1 (en) * 2002-05-17 2011-11-16 Janssen Pharmaceutica NV Aminotetralin-derived urea modulators of vanilloid vr1 receptor
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
CA2539227A1 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
ZA200709961B (en) * 2005-05-10 2009-07-29 Vertex Pharma Bicyclic derivatives as modulators of ion channels
EP1888558B1 (en) 2005-05-16 2011-10-05 Vertex Pharmaceuticals, Inc. Bicyclic derivatives as modulators of ion channels
CA2611731A1 (en) * 2005-06-09 2006-12-14 Vertex Pharmaceuticals Incorporated Indane derivatives as modulators of ion channels
NZ567132A (en) 2005-09-09 2011-12-22 Vertex Pharma Bicyclic derivatives as modulators of voltage gated ion channels
AU2006304283B2 (en) 2005-10-12 2012-01-19 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
AU2006306367A1 (en) 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
EP2308872A1 (en) * 2005-12-21 2011-04-13 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US8293450B2 (en) * 2006-11-28 2012-10-23 Hewlett-Packard Development Company, L.P. Laser imaging coating and methods for imaging
EP2158183A2 (en) * 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
CA2705336A1 (en) 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
RU2010123876A (ru) 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
CN102099356A (zh) * 2008-07-01 2011-06-15 沃泰克斯药物股份有限公司 用作离子通道调节剂的杂环衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Philip D. Stein et al..Discovery and Structure-Activity Relationships of Sulfonamide ETA-Selective Antagonists.《Journal of Medicinal Chemistry》.1995,第38卷(第8期),第1344-1354页.
Philip D. Stein et al..Discovery and Structure-Activity Relationships of Sulfonamide ETA-Selective Antagonists.《Journal of Medicinal Chemistry》.1995,第38卷(第8期),第1344-1354页. *
Philip D. Stein et al..The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ETA Antagonist 5-(Dimethylamino)-N- (3,4-dimethyl-5-isoxazoly1)- l-naphthalenesulfonamide.《Journal of Medicinal Chemistry》.1994,第37卷(第3期),第329-331页. *
PhilipD.Steinetal..TheDiscoveryofSulfonamideEndothelinAntagonistsandtheDevelopmentoftheOrallyActiveETAAntagonist5-(Dimethylamino)-N-(3 4-dimethyl-5-isoxazoly1)- l-naphthalenesulfonamide.《Journal of Medicinal Chemistry》.1994
Robert H. Bradbury et al..New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological，Properties, and Structure-Activity Relationships of 5-(Dimethylamino)-N-pyridyl-, -N-pyrimidinyl-, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides.《Journal of Medicinal Chemistry》.1997,第40卷(第6期),第996-1004页.
Robert H. Bradbury et al..New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological,Properties, and Structure-Activity Relationships of 5-(Dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and-N-pyrazinyl-1-naphthalenesulfonamides.《Journal of Medicinal Chemistry》.1997,第40卷(第6期),第996-1004页. *

Also Published As

Publication number Publication date
AU2006287480B2 (en) 2012-07-05
RU2008113836A (ru) 2009-10-20
EP1928871A2 (en) 2008-06-11
IL190017A0 (en) 2008-08-07
US20120308606A1 (en) 2012-12-06
US20070203130A1 (en) 2007-08-30
WO2007030618A3 (en) 2007-05-31
US20130131109A1 (en) 2013-05-23
US20110112156A1 (en) 2011-05-12
NZ567132A (en) 2011-12-22
US8492403B2 (en) 2013-07-23
JP2009507851A (ja) 2009-02-26
WO2007030618A2 (en) 2007-03-15
CA2622076A1 (en) 2007-03-15
NO20081725L (no) 2008-06-09
KR20080044910A (ko) 2008-05-21
US8357702B2 (en) 2013-01-22
AU2006287480A8 (en) 2012-02-02
CN101300253A (zh) 2008-11-05
US7855220B2 (en) 2010-12-21
ZA200802977B (en) 2009-08-26
US8236829B2 (en) 2012-08-07
MX2008003337A (es) 2008-09-26
AU2006287480A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
US7989481B2 (en) Indane derivatives as modulators of ion channels
US8236833B2 (en) Biphenyl derivatives as modulators of voltage gated ion channels
US8362032B2 (en) Bicyclic derivatives as modulators of ion channels
US8492403B2 (en) Bicyclic derivatives as modulators of voltage gated ion channels
US8314125B2 (en) Bicyclic derivatives as modulators of ion channels
HK1119433B (en) Indane derivatives as modulators of ion channels
HK1125365A (en) Biphenyl derivatives as modulators of voltage gated ion channels
HK1123042A (en) Bicyclic derivatives as modulators of voltage gated ion channels

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123042

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822

Termination date: 20130908

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1123042

Country of ref document: HK